Format

Send to

Choose Destination
Theor Biol Med Model. 2019 May 28;16(1):10. doi: 10.1186/s12976-019-0106-4.

The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia.

Author information

1
Department of Economic Theory and IMUVA, Faculty of Economics, Avda. Valle Esgueva 6, University of Valladolid, Valladolid, 47011, Spain. pedrojos@fae.uva.es.
2
Department of Applied Mathematics and IMUVA, Faculty of Science, University of Valladolid, Paseo de Belén 7, Valladolid, 47011, Spain.
3
Department of Applied Economics and IMUVA, Faculty of Economics, University of Valladolid, Avda. Valle Esgueva 6, Valladolid, 47011, Spain.
4
Director of the Breast Cancer Research Laboratory, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, 19111-2497, PA, USA.

Abstract

BACKGROUND:

The mathematical design of optimal therapies to fight cancer is an important research field in today's Biomathematics and Biomedicine given its relevance to formulate patient-specific treatments. Until now, however, cancer optimal therapies have considered that malignancy exclusively depends on the drug concentration and the number of cancer cells, ignoring that the faster the cancer grows the worse the cancer is, and that early drug doses are more prejudicial. Here, we analyze how optimal therapies are affected when the time evolution of treated cancer is envisaged as an additional element determining malignancy, analyzing in detail the implications for imatinib-treated Chronic Myeloid Leukemia.

METHODS:

Taking as reference a mathematical model describing Chronic Myeloid Leukemia dynamics, we design an optimal therapy problem by modifying the usual malignancy objective function, unaware of any temporal dimension of cancer malignance. In particular, we introduce a time valuation factor capturing the increase of malignancy associated to the quick development of the disease and the persistent negative effects of initial drug doses. After assigning values to the parameters involved, we solve and simulate the model with and without the new time valuation factor, comparing the results for the drug doses and the evolution of the disease.

RESULTS:

Our computational simulations unequivocally show that the consideration of a time valuation factor capturing the higher malignancy associated with early growth of cancer and drug administration allows more efficient therapies to be designed. More specifically, when this time valuation factor is incorporated into the objective function, the optimal drug doses are lower, and do not involve medically relevant increases in the number of cancer cells or in the disease duration.

CONCLUSIONS:

In the light of our simulations and as biomedical evidence strongly suggests, the existence of a time valuation factor affecting malignancy in treated cancer cannot be ignored when designing cancer optimal therapies. Indeed, the consideration of a time valuation factor modulating malignancy results in significant gains of efficiency in the optimal therapy with relevant implications from the biomedical perspective, specially when designing patient-specific treatments.

KEYWORDS:

Chronic myeloid leukemia; Hematopoiesis; Imatinib therapy; Optimal control problem; System of difference equations; Time valuation factor

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center